Efficacy of a Modified Treat-and-Extend Aflibercept Regimen for Macular Oedema in Eyes with Central Retinal Vein Occlusion: 2-Year Prospective Study.
anti-vascular endothelial growth factor
central retinal vein occlusion
modified treat-and-extend regimen
personalized therapy
prospective multicenter intervention study
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
02 Aug 2023
02 Aug 2023
Historique:
received:
07
06
2023
revised:
24
07
2023
accepted:
31
07
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
This prospective, multicentre, interventional study evaluated the efficacy of a modified treat-and-extend (mTAE) aflibercept regimen as personalized therapy for macular oedema (MO) due to central retinal vein occlusion (CRVO). Fifty eyes were studied from 50 patients who were enrolled between November 2016 and July 2019. All patients received intravitreal aflibercept (IVA) injections on an mTAE regimen for 24 months. Primary outcome measures were best-corrected visual acuity (BCVA) and central subfield thickness (CST) at 12 months. Secondary endpoints were BCVA and CST at 24 months. Mean (standard deviation) baseline BCVA (logMAR) and CST were 0.50 (0.51) and 557 (240) µm, respectively. BCVA and CST showed significant improvements at month 12 (0.19 (0.38) and 275 (98) µm, respectively; both
Identifiants
pubmed: 37568491
pii: jcm12155089
doi: 10.3390/jcm12155089
pmc: PMC10419814
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Am J Ophthalmol. 2011 Aug;152(2):298-303.e1
pubmed: 21621189
Ophthalmology. 2014 Jan;121(1):202-208
pubmed: 24084497
Ophthalmology. 2014 Jan;121(1):209-219
pubmed: 24112944
Retina. 2010 Oct;30(9):1524-9
pubmed: 20664492
Eye (Lond). 2016 Apr;30(4):505-14
pubmed: 26869163
Ophthalmology. 2012 Apr;119(4):802-9
pubmed: 22301066
J Glob Health. 2019 Jun;9(1):010427
pubmed: 31131101
Ophthalmology. 2011 Jan;118(1):119-133.e1-2
pubmed: 20723991
Ophthalmology. 2011 Oct;118(10):2041-9
pubmed: 21715011
Acta Ophthalmol. 2012 Mar;90(2):e98-e103
pubmed: 22066978
Ophthalmology. 2014 Dec;121(12):2432-42
pubmed: 25060610
Retina. 2015 Aug;35(8):1489-506
pubmed: 26076215
Ophthalmology. 2014 Jul;121(7):1414-1420.e1
pubmed: 24679444
J Clin Med. 2020 Jul 23;9(8):
pubmed: 32718095
Retina. 2014 Aug;34(8):1531-8
pubmed: 24637667
Am J Ophthalmol. 2013 Mar;155(3):429-437.e7
pubmed: 23218699
Am J Ophthalmol. 2007 Apr;143(4):679-80
pubmed: 17386275
Am J Ophthalmol. 2005 Aug;140(2):256-61
pubmed: 16086947
Br J Ophthalmol. 2017 May;101(5):574-579
pubmed: 27503394
Ophthalmol Retina. 2018 Feb;2(2):134-142
pubmed: 31047340
J Clin Med. 2021 Jul 17;10(14):
pubmed: 34300328
BMC Ophthalmol. 2020 Feb 24;20(1):69
pubmed: 32093666
J Ophthalmol. 2018 Oct 14;2018:8310350
pubmed: 30405907
Ophthalmol Retina. 2020 Aug;4(8):767-776
pubmed: 32417356
Ophthalmol Retina. 2021 Nov;5(11):1177-1179
pubmed: 34174497